

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

## **M.8146 - CARLYLE / SCHÖN KLINIK**

### **SECTION 1.2**

#### **Description of the concentration**

Mr. Dieter Schön (“**DS**”), his spouse Dr. Susanne Nolte-Schön (“**SNS**”) and their sons Mr. Christopher Schön (“**CS**”) and Mr. Constantin Schön (collectively the “**Schön Family**”) are the sole – direct and indirect – owners of SKS, the ultimate parent company of the Schön hospitals.

The Schön Family is actively engaged in the management of SKS. DS is the CEO, chairman of the board and managing director of SKS. CS is the COO of SKS. Besides its direct and indirect shareholding in SKS, the Schön Family also controls Silony Medical International AG and its subsidiaries (together “**Silony Group**”), Orthopädietechnik Chiemgau GmbH (“**OTC**”) and Orthopädietechnik München Harlaching GmbH (“**OTM**”). Silony Group mainly develops and produces spinal and endoprosthetic implants and instruments as living systems whilst OTC and OTM are suppliers of a broad range of orthopaedic products (e.g., foot/leg/arm/hand orthotics). Other than that, the Schön Family merely holds interests in holding companies which manage private assets of the Schön Family and in shelf companies which do not yet have any business activities.

The relevant members of the Schön Family remain involved in the management of SKS following completion of the concentration. DS, SNS and CS will become initial members of SKS’ board of directors. Further, serving as two of the three initial managing directors DS and CS will remain CEO and COO of SKS.